These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35576048)

  • 21. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T; Stowasser S; Goeldner RG; Schlenker-Herceg R; Brown KK;
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.
    Song JW; Ogura T; Inoue Y; Xu Z; Quaresma M; Stowasser S; Stansen W; Crestani B
    Respirology; 2020 Apr; 25(4):410-416. PubMed ID: 31329360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
    Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
    Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.
    Matteson EL; Aringer M; Burmester GR; Mueller H; Moros L; Kolb M
    Clin Rheumatol; 2023 Sep; 42(9):2311-2319. PubMed ID: 37209188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.
    Flaherty KR; Kolb M; Vancheri C; Tang W; Conoscenti CS; Richeldi L
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
    Cottin V; Martinez FJ; Jenkins RG; Belperio JA; Kitamura H; Molina-Molina M; Tschoepe I; Coeck C; Lievens D; Costabel U
    Respir Res; 2022 Apr; 23(1):85. PubMed ID: 35392908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.
    Mira-Avendano I; Kaye M
    Ther Adv Respir Dis; 2024; 18():17534666241266343. PubMed ID: 39113425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subgroup analysis of Asian patients in the INPULSIS
    Taniguchi H; Xu Z; Azuma A; Inoue Y; Li H; Fujimoto T; Bailes Z; Schlenker-Herceg R; Kim DS
    Respirology; 2016 Nov; 21(8):1425-1430. PubMed ID: 27399197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
    Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
    Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach.
    Maher TM; Brown KK; Cunningham S; DeBoer EM; Deterding R; Fiorino EK; Griese M; Schwerk N; Warburton D; Young LR; Gahlemann M; Voss F; Stock C;
    Pediatr Pulmonol; 2024 Apr; 59(4):1038-1046. PubMed ID: 38289091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
    Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
    N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subgroup Analysis for Chinese Patients Included in the INPULSIS
    Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
    Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
    Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
    Costabel U; Inoue Y; Richeldi L; Collard HR; Tschoepe I; Stowasser S; Azuma A
    Am J Respir Crit Care Med; 2016 Jan; 193(2):178-85. PubMed ID: 26393389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
    Wuyts WA; Kolb M; Stowasser S; Stansen W; Huggins JT; Raghu G
    Lung; 2016 Oct; 194(5):739-43. PubMed ID: 27377558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.
    Allanore Y; Vonk MC; Distler O; Azuma A; Mayes MD; Gahlemann M; James A; Kohlbrenner V; Alves M; Khanna D; Highland KB;
    Ann Rheum Dis; 2022 Dec; 81(12):1722-1729. PubMed ID: 35973804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
    Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
    Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
    Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.